SHANGHAI, March 5, 2018 /PRNewswire/ -- WuXi Biologics (Stock Code: 2269.HK), a leading globalopen-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, announced that based on the preliminary assessment of the unaudited consolidated management accounts of the Company
During the Reporting Period, the Company incurred an unrealized foreign exchange loss due to a translation loss from the IPO proceeds (in U.S. Dollar) to Renminbi as a result of Renminbi appreciation against the U.S. Dollar. If the unrealized foreign exchange loss is excluded, the Company's net profit for the year ended December 31, 2017 is expected to be approximately RMB321 million to RMB328 million, representing a year-on-year growth of approximately 128% to 133%. Such an increase was primarily attributable to a strong growth in revenue driven by implementing the Company's "follow-the-molecule" strategy, and efficiency enhancement of the Company's business operation.
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
View original content:http://www.prnewswire.com/news-releases/wuxi-biologics-announces-positive-profit-alert-300607935.html
SOURCE WuXi Biologics
Subscribe to our Free Newsletters!
Self-medication is treating self with non-prescription or over the counter medications, for ...
Art of gardening can improve socializing and cognitive skills in children and elderly. As a therapy ...
Prunes are dried plums that are packed with nutrients like vitamins and minerals that are essential ...View All